文献速递儿科影像腹部MR

已知或疑似克罗恩病儿科患者磁共振小肠造影三种口服对比剂准备的比较:一项前瞻性随机试验

Comparison of three oral contrast preparations for magnetic resonance enterography in pediatric patients with known or suspected Crohn disease: a prospective randomized trial.
PubMed 文献 · Pediatr Radiol · 2019-03-09

本前瞻性随机试验纳入75例已知或疑似克罗恩病的儿科患者,比较三种口服对比剂(Breeza、MiraLAX、VoLumen)的耐受性与磁共振小肠造影图像质量。MiraLAX和Breeza的口感评分优于VoLumen,MiraLAX的完成率高于VoLumen,但三组小肠扩张和充盈程度无显著差异。

要点

  • MiraLAX和Breeza口感优于VoLumen,且MiraLAX完成率更高。
  • 三种口服对比剂对小肠扩张和充盈的影像学评价无显著差异。
  • 影像中心应储备多种口服对比剂,因相当比例儿童需更换制剂。

核心结论

  • 在已知或疑似克罗恩病的儿科患者中,MiraLAX和Breeza口感评分优于VoLumen,三种制剂在小肠扩张和充盈程度上相似。

研究设计与样本

  • 前瞻性随机试验,纳入75例已知或疑似克罗恩病的儿科患者(平均年龄14.8岁,55%女性),随机分配至Breeza、MiraLAX或VoLumen口服准备组,采用基于体重的方案于MRE前60分钟开始服用。

关键影像表现/征象

  • 整体小肠扩张和肠段特异性指标(扩张程度、最大管径、充盈和磁化率伪影)在三组间无显著差异。

诊断标准与关键数值

  • 总体完成全部处方对比剂剂量的比例为53%(40/75),MiraLAX组完成率70% vs VoLumen组30%,P=0.007。
  • 更换准备方案发生在9例患者(12%),初始为VoLumen者更换频率29% vs 初始为MiraLAX者0%,P=0.005。
  • MiraLAX平均主观口感评分3.4(P<0.0001)和Breeza 2.8(P=0.006)均优于VoLumen 1.9,在MRE证实活动性克罗恩病的亚组中持续存在。
  • MiraLAX组再次饮用意愿82% vs VoLumen组46%,P=0.009。

临床应用与阅片要点

  • 影像中心应储备多种口服对比剂,因为相当比例儿童需要一种以上制剂来摄入所需口服对比剂体积。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Oral contrast preparation is fundamental to ensuring diagnostic examination quality for magnetic resonance enterography (MRE), yet little is known about the relative palatability and tolerability of various oral contrast agents in pediatric patients with known or suspected inflammatory bowel disease.

OBJECTIVE: We prospectively compared three MRE oral preparations in pediatric patients with known or suspected Crohn disease with respect to patient-reported tolerability and radiologist-determined small-bowel distension and opacification.

MATERIALS AND METHODS: Seventy-five pediatric patients (mean age 14.8 years, 55% female) with known or suspected Crohn disease referred for MRE were randomized to an oral preparation with a sugar alcohol-based flavored beverage (Breeza), polyethylene glycol preparation (MiraLAX), or low-concentration barium sulfate suspension (VoLumen). Patients were instructed to consume oral contrast agent (using a weight-based protocol) beginning 60 min prior to MRE imaging. Following MRE, patients completed a questionnaire regarding their oral preparation solution including: taste (1-5 scale), feeling of well-being (1-5 scale) and willingness to consume again (yes/no). Two radiologists reviewed all MRE exams and rated exams for global features (active disease, overall small-bowel distention [1-4 scale]) and features specific to individual small-bowel segments (extent of distention, maximal luminal diameter, opacification, and susceptibility artifact). Statistical methods included one-way analysis of variance (ANOVA) with Tukey honest difference and Fisher exact tests.

RESULTS: The overall rate of completion of the entire prescribed contrast volume was 53% (40/75), with a significantly higher rate of completion for MiraLAX than for VoLumen (70% vs. 30%, P=0.007). Crossover to a different preparation occurred in nine patients (12%) and was significantly more frequent when the initial preparation was VoLumen versus MiraLAX (29% vs. 0%, P=0.005). Mean subjective taste ratings for both MiraLAX (3.4, P<0.0001) and Breeza (2.8, P=0.006) were superior to those of VoLumen (1.9), which persisted in the subset of patients with MRE evidence of active Crohn disease. Patients who consumed MiraLAX were more likely to be willing to drink it again compared to those consuming VoLumen (82% vs. 46%, P=0.009). Overall small-bowel distention and bowel-segment-specific metrics (distention, maximal diameter, opacification and susceptibility) did not significantly differ among groups.

CONCLUSION: In pediatric patients with known or suspected Crohn disease, MiraLAX and Breeza were rated as more palatable than VoLumen, and all three preparations achieved a similar degree of small-bowel distension and opacification on MRE. Imaging centers performing MRE should stock multiple oral contrast preparations because a sizable proportion of children require more than one agent to ingest the requisite oral contrast volume.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Gottumukkala RV, LaPointe A, Sargent D, et al. Comparison of three oral contrast preparations for magnetic resonance enterography in pediatric patients with known or suspected Crohn disease: a prospective randomized trial. Pediatr Radiol. 2019. PMID: 30852650. doi:10.1007/s00247-019-04378-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。